Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·· 1 day agoScore70
Body
Overall survival numerically favored abemaciclib + fulvestrant following disease progression on prior Al/CDK4/6i; median 32.1 vs 24.6 months
HR 0.80, 95% CI 0.60-1.06) @KalinskyKevin @OncoAlert #ESMO26
118 views · 4 likes · 4 reposts · 0 replies
Conference abstracts
1ROmatched by Rapid oral 1: Breast cancer, advanced stage
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.orgAssociation of p27 V109G SNP zygosity with outcomes and abemaciclib treatment effect in HR+, HER2– high-risk early breast cancer: Results from monarchE
https://esmocongress.esmo.orgSource: Stephanie Graff, MD, FACP, FASCO · x.com